A photosensitizer loaded hemoglobin–polymer conjugate as a nanocarrier for enhanced photodynamic therapy†,Journal of Materials Chemistry B

当前位置： X-MOL 学术 › J. Mater. Chem. B › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A photosensitizer loaded hemoglobin–polymer conjugate as a nanocarrier for enhanced photodynamic therapy†
Journal of Materials Chemistry B ( IF 6.1 ) Pub Date : 2018-01-31 00:00:00 , DOI: 10.1039/c7tb03109b
Xin Xu _{1,

2,

3,

4,

5} , Yuecheng Cui _{1,

2,

3,

4,

5} , Huixuan Bu _{1,

2,

3,

4,

5} , Jiaming Chen _{1,

2,

3,

4,

5} , Yang Li _{3,

6,

7,

8} , Guping Tang _{3,

6,

7,

8} , Li-Qun Wang _{1,

2,

3,

4,

5}

Affiliation

Photodynamic therapy (PDT) has emerged as a promising therapeutic option for various cancers. During the photosensitizer-mediated PDT procedure, oxygen is activated as a reactive oxygen species (ROS) upon light irradiation to induce vascular damage and cancer cell death directly. However, PDT efficiency can be seriously reduced in the hypoxic environment of the tumour. Even worse, the oxygen consumption of PDT aggravates the hypoxia, which leads to further PDT inefficiency and other negative consequences. Herein, a new kind of hemoglobin–polymer conjugate (HbTcMs) was prepared as the carrier for both oxygen and the photosensitizer to enhance photodynamic therapy. The conjugated Hb exhibited an improved tolerance to the oxidation and trypsin digestion while retaining its O₂ binding capacity compared with free Hb. The HbTcMs conjugate showed little toxicity in the dark and could be effectively internalized by 4T1 cells. More importantly, the HbTcMs conjugate could readily produce singlet oxygen (¹O₂) and kill 4T1 cells in vitro under irradiation, exerting better phototoxicity with the oxygen supply of Hb. Therefore, it is expected that the HbTcMs conjugate can be a potential oxygen carrier for application in photodynamic therapy.

中文翻译：

载有光敏剂的血红蛋白-聚合物共轭物作为纳米载体，可增强光动力疗法†

光动力疗法（PDT）已经成为各种癌症的有前途的治疗选择。在光敏剂介导的PDT程序中，氧气在光照射下被活化为活性氧（ROS），直接导致血管损伤和癌细胞死亡。但是，在肿瘤的低氧环境中，PDT的效率会严重降低。更糟的是，PDT的氧气消耗加剧了缺氧，导致进一步的PDT低效和其他负面后果。在此，准备了一种新型的血红蛋白-聚合物共轭物（HbTcMs）作为氧气和光敏剂的载体，以增强光动力疗法。结合的Hb在保留其O _2的同时，对氧化和胰蛋白酶消化表现出更高的耐受性与游离Hb的结合能力。HbTcMs缀合物在黑暗中几乎没有毒性，可以被4T1细胞有效内化。更重要的是，HbTcMs共轭物可以很容易地产生单线态氧（¹ O ₂）并在辐射下在体外杀死4T1细胞，从而通过Hb的氧供应产生更好的光毒性。因此，期望HbTcMs缀合物可以是潜在的氧载体，用于光动力疗法。

更新日期：2018-01-31

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11